Retrospective Cohort Study of Effectiveness and Safety of Adalimumab Use in Children with Juvenile Idiopathic Arthritis in the Republic of Bashkortostan

Retrospective Cohort Study of Effectiveness and Safety of Adalimumab Use in Children with Juvenile Idiopathic Arthritis in the Republic of Bashkortostan

Background: Methotrexate is the first-line drug for treating patients with juvenile idiopathic arthritis (JIA). If it is ineffective or intolerable, prescription of genetically engineered biopharmaceuticals is indicated. Objective: The study was aimed at assessing effectiveness and safety of genetic...

Full description

Saved in:
Bibliographic Details
Main Authors: V. A. Maliyevskiy, O. A. Maliyevskiy, G. R. Gareyeva, L. S. Nazarova, A. A. Khasanova, A. Z. Nuriyakhmetova, D. D. Prolygina
Format: Article
Language:Russian
Published: Union of pediatricians of Russia 2016-02-01
Series:Педиатрическая фармакология
Subjects:
children
juvenile idiopathic arthritis
genetically engineered biopharmaceuticals
adalimumab
Online Access:https://www.pedpharma.ru/jour/article/view/1367
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.pedpharma.ru/jour/article/view/1367

Similar Items